JP2024516199A5 - - Google Patents

Info

Publication number
JP2024516199A5
JP2024516199A5 JP2023565369A JP2023565369A JP2024516199A5 JP 2024516199 A5 JP2024516199 A5 JP 2024516199A5 JP 2023565369 A JP2023565369 A JP 2023565369A JP 2023565369 A JP2023565369 A JP 2023565369A JP 2024516199 A5 JP2024516199 A5 JP 2024516199A5
Authority
JP
Japan
Prior art keywords
formula
compound
reacting
hcl
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565369A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516199A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/026208 external-priority patent/WO2022232060A1/en
Publication of JP2024516199A publication Critical patent/JP2024516199A/ja
Publication of JP2024516199A5 publication Critical patent/JP2024516199A5/ja
Pending legal-status Critical Current

Links

JP2023565369A 2021-04-26 2022-04-25 バルベナジンの合成方法 Pending JP2024516199A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163180043P 2021-04-26 2021-04-26
US63/180,043 2021-04-26
US202163286764P 2021-12-07 2021-12-07
US63/286,764 2021-12-07
PCT/US2022/026208 WO2022232060A1 (en) 2021-04-26 2022-04-25 Processes for the synthesis of valbenazine

Publications (2)

Publication Number Publication Date
JP2024516199A JP2024516199A (ja) 2024-04-12
JP2024516199A5 true JP2024516199A5 (https=) 2025-05-08

Family

ID=81654703

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565369A Pending JP2024516199A (ja) 2021-04-26 2022-04-25 バルベナジンの合成方法

Country Status (6)

Country Link
US (1) US20240239791A1 (https=)
EP (1) EP4330255A1 (https=)
JP (1) JP2024516199A (https=)
CA (1) CA3215792A1 (https=)
IL (1) IL307826A (https=)
WO (1) WO2022232060A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026050236A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081929B1 (en) 2006-11-08 2013-01-09 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
RS61645B1 (sr) 2015-10-30 2021-04-29 Neurocrine Biosciences Inc Valbenazin ditozilat i njihovi polimorfi
JP6869988B2 (ja) * 2015-12-23 2021-05-12 ニューロクライン バイオサイエンシーズ,インコーポレイテッド (S)−(2R,3R,11bR)−3−イソブチル−9,10−ジメトキシ−2,3,4,6,7,11b−ヘキサヒドロ−1H−ピリド[2,1−a]イソキノリン−2−イル2−アミノ−3−メチルブタノエートジ(4−メチルベンゼンスルホネート)の調製のための合成方法
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
CA3150961A1 (en) * 2019-09-13 2021-03-18 John Tucker Processes for the synthesis of valbenazine

Similar Documents

Publication Publication Date Title
DK2091910T3 (en) Crystalline forms of (3S) -3- [N- (N '- (2-tert-butylphenyl) oxamyl) alaninyl] amino-5- (2', 3 ', 5', 6'-tetrafluorophenoxy) -4-oxopentanoic acid
JP2008509953A5 (https=)
US8530668B2 (en) Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
JP2015518891A (ja) 抗ウイルス化合物の固体形態
JP2022511029A5 (https=)
CA3119807A1 (en) Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
JP2021523208A5 (https=)
JP6215399B2 (ja) ナルトレキソンの製造方法
JP2025539576A (ja) イミダゾリノン化合物の医薬製剤、その調製方法及びその使用
JP2024516199A5 (https=)
WO2002020539A1 (en) Adenosine derivatives and use thereof
ES2331487T3 (es) Forma cristalina estable de bifeprunox mesilato, formas de dosificacion del mismo y metodos de utilizacion.
HU203766B (en) Process for producing estramustine-esters and pharmaceutical compositions containing them as active components
US20080234323A1 (en) Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride
ES2651962T3 (es) Derivados de bis-MMF
US20110269838A1 (en) Novel processes and pure polymorphs
JPS58208275A (ja) 5−アミノ−ピラゾ−ル誘導体及び該化合物を含有する抗腫瘍剤
CA2483054A1 (en) Carvedilol monocitrate monohydrate
WO1993023360A1 (en) Novel quaternary ammonium salts and use thereof as medicine
KR20040074134A (ko) 2'-할로-3',5'-디알콕시펜-1'-일-이미노-2-이미다졸리딘유도체 및 요실금의 치료를 위한 이의 용도
US8754129B2 (en) Crystalline vorinostat form VI
CH641773A5 (fr) Derives de 6-methoxy-2-acetylnaphtalene oxime, procede de leur preparation et medicament comportant de ces derives.
CN112979572B (zh) 一种帕瑞昔布衍生物及其制备方法和应用
JP6421873B2 (ja) テノホビルジソプロキシルの新規塩
CN113501846B (zh) 艾美酚胺替诺福韦半富马酸复合物、晶型及其制备方法和应用